Related Experiment Video
Updated: Aug 1, 2025

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
Published on: December 26, 2015
Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical
Marc Thibonnier1, Sujoy Ghosh2
1AptamiR Therapeutics, Inc., Austin, TX 78759, USA.
Abstract:
We present here an innovative modular and outsourced model of drug research and development for microRNA oligonucleotide therapeutics (miRNA ONTs). This model is being implemented by a biotechnology company, namely AptamiR Therapeutics, in collaboration with Centers of Excellence in Academic Institutions. Our aim is to develop safe, effective and convenient active targeting miRNA ONT agents for the metabolic pandemic of obesity and metabolic-associated fatty liver disease (MAFLD), as well as deadly ovarian cancer.
Related Concept Videos
MicroRNAs
Targeted Cancer Therapies
There are several types of targeted therapies against...
Microorganisms in Medicine and Therapeutics
Preclinical Development: Overview
Drug Discovery: Overview

